Three distinct hematological malignancies from a single germ cell tumor: a case report

M. Spencer Chapman1,2*, P. C. May3, E. Olavarria2 and E. Nadal Melsio4

Abstract

Background: The association between non seminomatous germ cell tumors (GCTs) and hematological malignancies of rare lineage has been described in the literature. In some of these cases there is evidence that the leukemia derives from a pluripotent primitive clone present in the original germ cell tumor.

Case presentation: We present a highly unusual case of a 23-year-old man of South Asian origin with a history of Klinefelter’s syndrome who initially developed mediastinal non seminomatous GCT. Following treatment with surgery and standard chemotherapy he went on to develop three different hematological malignancies of distinct lineages in sequential fashion over a short time period. Despite treatment with multiple intensive chemotherapy regimens and a matched unrelated donor allogeneic stem cell transplant, he died 41 months after initial diagnosis of his GCT and 10 months after the first diagnosis of hematological malignancy.

Conclusions: This is an extreme case that highlights the pluripotency and aggressiveness of these GCT-derived hematological malignancies, and the need for novel therapeutic approaches.

Keywords: Germ cell tumor, Teratoma, Mediastinal non seminomatous germ cell tumor, Acute myeloid leukemia, AML, Burkitt’s lymphoma, Klinefelter’s syndrome, Malignant transformation, Clonal evolution

Background

The majority of male germ cell tumors (GCTs) are located within the testis, however extra-gonadal GCTs represent 1 to 5% of all GCTs and have varied morphology and anatomic location including the anterior mediastinum and retroperitoneum [1]. As a malignancy of primitive cells, GCTs display pluripotentiality for extra-embryonal and embryonal (somatic) differentiation [2, 3]. Among all GCTs, teratomas show the most vivid and varied patterns of somatic differentiation with multiple mature and immature elements [4]. Rarely, teratomas undergo further “malignant transformation” whereby aggressive proliferation of a differentiated non-germ cell tissue develops [5]. This includes neurogenic, epithelial, mesenchymal and hematopoietic malignancies which are often indistinguishable from their spontaneous counterparts, their GCT origin shown only by genetic markers [6, 7]. Where hematopoietic malignancies develop, they are frequently unusual histologic subtypes (e.g. megakaryoblastic leukemia, histiocytic malignancies) and follow an aggressive clinical course [8]. However, they generally remain of one histologic subtype over time. We report an unusual case of a 23-year-old man with Klinefelter’s syndrome and previously treated mediastinal teratoma who went on to develop three different hematological malignancies of distinct lineages in sequential fashion over a short time period.

Case report

A 23-year-old male of South Asian origin with mosaic Klinefelter syndrome was diagnosed with mediastinal non seminomatous GCT (see Fig. 1 for timeline). Initial management was with surgical resection. At this time the full blood count was normal. Histology confirmed
complete excision with narrow margins. Four months later he relapsed with rising levels of beta-human chorionic gonadotrophin (ß-HCG). He was treated with alternating POMB (vincristine 2 mg IV and methotrexate 300 mg/m² over 24 h on day 1, bleomycin 15 mg IV over 24 h on days 2 and 3, cisplatin 120 mg/m² IV over 12 h on day 4) and ACE (dactinomycin 0.5 mg IV on days 1–3, etoposide 500 mg/m² IV on day 3) chemotherapy, but due to a severe reaction to cisplatin and a presumed treatment-related cerebrovascular accident, cisplatin was substituted with carboplatin. He completed 2 cycles, resulting in biochemical remission.

Twenty-three months later he developed thrombocytopenia, macrocytic anaemia, and a raised serum lactate dehydrogenase associated with epistaxis, fatigue and backache. Biochemical markers for GCT remained low. Bone marrow (BM) aspirate showed severe dysplastic changes in all three hematopoietic lineages with 6% myeloblasts classifying him as myelodysplastic syndrome with excess blasts-1 (MDS-EB1) (Fig. 2a). Karyotyping of the BM revealed an abnormal hypotriploid karyotype, with various numerical gains including trisomy 8 and tetrasomy 22, and a single structural abnormality, an isochromosome comprising two copies of the long arm of chromosome 15 (Fig. 2b).

This was an unusual karyotype for MDS and given the high risk of leukemic transformation, he was planned for allogeneic hematopoietic stem cell transplantation (HSCT).

Only 2 weeks after the first BM study and during work-up for HSCT, he developed rapidly worsening cytopenias with peripheral blasts. Repeat BM biopsy now showed infiltration with TdT positively staining cells consistent with acute lymphoblastic leukemia (ALL) with L3 morphology (Fig. 3a). The cytogenetic study revealed an abnormal male karyotype with a new t(8; 22) (q24;q11) with MYC rearrangement confirmed with FISH, plus other chromosomal abnormalities; a single euploid cell carrying an isochromosome 15 was noted (Fig. 3b, c).

He received induction chemotherapy according to the UK-ALL14 trial protocol [9] (complex regimen including cytarabine, daunorubicin, vincristine, dexamethasone, peg-asparaginase, methotrexate, cyclophosphamide and mercaptopurine) achieving complete morphologic and cytogenetic remission of ALL but with persistent trisomy 8 in 12% of cells examined by FISH. He proceeded to a matched unrelated donor allogeneic HSCT with reduced intensity conditioning with alemtuzumab (10 mg IV daily on days −7 to −3), fludarabine (30 mg/m² IV daily on days −7 to −3) and melphalan (140 mg/m² IV on day −2) and prophylaxis of graft-versus-host disease with post-transplantation methotrexate (8 mg/m² IV daily on days +2, +4 and +8). Hematological recovery occurred by day +40. A BM study on day +71 post-transplant, performed due to new progressive thrombocytopenia, demonstrated complete cytogenetic remission of the ALL clone, and FISH analysis again showed persistence of trisomy 8 in 9% of examined cells.
One week later he developed tonsillitis, worsening thrombocytopenia necessitating frequent platelet transfusions, and severe opiate-refractory bone pains most marked in the right knee. MRI of the knee showed extensive lytic lesions. Severe sepsis and visual impairment resulting from bilateral retinal hemorrhages then developed. BM study now showed 87% infiltration with abnormal erythroblasts (Fig. 4a) and no evidence of abnormal lymphoid precursors. A diagnosis of pure erythroid leukemia was made. Karyotyping of the BM revealed an abnormal hyperdiploid karyotype, with both structural and numerical abnormalities. FISH for the
MYC rearrangement remained negative, confirming that this was a new lineage malignancy unrelated to the ALL (Fig. 4b).

FLAG-IDA chemotherapy (fludarabine 30 mg/m² IV for 4 days, cytarabine 2 g/m² IV for 4 days, G-CSF 480 µg from day − 1 until day 5, and idarubicin 10 mg/m² for 3 days) was administered followed by CD34+ stem cell top-up. The patient declined further inpatient treatment and was discharged on day 11 post-chemotherapy. Unfortunately, he died at home 2 weeks later, 41 months after initial diagnosis of GCT, and 10 months after diagnosis of his first hematologic malignancy.

Discussion
Klinefelter syndrome is the most common constitutional abnormality of the sex chromosomes and is present in an estimated 1/500 to 1/1000 males [10]. Several studies have demonstrated an association between Klinefelter and non seminomatous GCTs as well as breast cancer, lung cancer, and non-Hodgkin lymphoma [11–13]. This increased prevalence may reflect either the role of an extra X chromosome in these tumors or a developmental defect in the migration of germ cells in Klinefelter syndrome [14, 15].

The pluripotency of malignant transformation in GCT has long been recognised both within the original tumor and at metastatic sites [16]. Sarcoma is the most frequent subtype (63%), though adenocarcinoma, primitive neuroectodermal tumor and hematologic neoplasia are all well recognised. The cytogenetic abnormality isochromosome 12p (“i(12p”) in GCT is well established, with a high prevalence in male GCT. In many cases the clonal origin of metastatic malignancies from the primary GCT is demonstrated by the persistence of this abnormality in the subsequent malignancy [17, 18]. The rare association of hematologic neoplasia and extragonadal germ cell tumors appears to be exclusive to mediastinal non seminomatous GCT with an incidence of 2% in this patient group in one case series of 287 patients [8]. The spectrum of hematologic disease in this setting is unusual, with a predominance of clonal megakaryocytic disorders (AML M7 [French–American–British classification] and MDS with abnormal megakaryocytes) but also mast cell and undifferentiated leukemias (Table 1 [7, 8, 17, 19–30]). Both lymphoblastic and acute erythroid leukemia have been described after or concurrent to GCT but to our knowledge this is the first case where three different sequential hematological malignancies of different lineages have been demonstrated (MDS, ALL and erythroleukemia). It is plausible that the relatively long survival of our patient compared to most of the published cases allowed the development of this wider range of malignancies.

Number in brackets indicates the number of cases with data on each feature. References for case reports included in table [7, 8, 17, 19–30].

Chemotherapeutic agents used in the initial regimen for this patient can cause therapy-related AML/MDS, with alkylating agents such as cyclophosphamide known to particularly cause monosomy of chromosomes 5 and 7. However previous case series have suggested that the

![Fig. 3](image-url)
Fig. 4  Erythroleukemia. a BM trephine roll showing infiltration by abnormal erythroblasts. ×40 (inset ×100) (Microscope Olympus BX50, camera iPhone SE). b Metaphase and interphase FISH using the same dual-colour break-apart probe for MYC showing no detectable rearrangement of MYC but instead an additional signal consistent with trisomy 8 [3F]

Table 1  Features of published cases of hematological malignancies post-germ cell tumor

| Feature                               | Median | Range          |
|---------------------------------------|--------|----------------|
| Patient age (49)                      |        | 23 years       |
| Patient sex (63)                      |        | Exclusively male|
| Anatomic location of prior GCT (75)   |        | Exclusively mediastinal |
| Histology of prior GCT (24)           |        | Variable and often mixed, including immature teratoma, yolk-sac tumour, undifferentiated histologies |
| Frequency of specific karyotypic abnormalities in hematological malignancy (40) | Presence of i(12p) | 68% |
|                                       | Presence of +8 | 29% |
|                                       | Complex karyotype (≥ 3 structural abnormalities) | 48% |
| Type of hematological malignancy (74) | AML    | 57%            |
|                                       | Histiocytic disorder | 10% |
|                                       | MDS (with megakaryocytic dysplasia) | 11% |
|                                       | Mast cell leukemia | 3% |
|                                       | ALL    | 4%             |
|                                       | Acute undifferentiated leukemia | 5% |
|                                       | MPN    | 7%             |
|                                       | Other  | 4%             |
| Morphological subtype of AML (where reported) (33) | M2 (Myeloblastic with maturation) | 9% |
|                                       | M3 (Promyelocytic) | 3% |
|                                       | M4 (Myelomonocytic) | 24% |
|                                       | M5 (Monocytic) | 9% |
|                                       | M6 (Erythroblastic) | 6% |
|                                       | M7 (Megakaryoblastic) | 48% |
| Time from GCT diagnosis to hematological malignancy (51) | Median | 4 months |
|                                       | Range  | 0–47 months    |
| Survival following GCT diagnosis (35) | Median | 5 weeks        |
|                                       | Maximum | 44 weeks       |

Recent case reports with allogeneic transplantation and/or novel targeted therapies have had better survival than previous case reports (> 40 weeks, n = 2), however, still none > 1 year

GCT germ cell tumor, i(12p) isochromosome 12p, AML acute myeloid leukemia, MDS myelodysplastic syndrome, ALL acute lymphoblastic leukemia, MPN myeloproliferative neoplasm; M2, M3, M4, M5, M6 and M7 refer to the corresponding French-American-British morphologic classification of acute myeloid leukemia
association of hematologic neoplasia following non seminomatous GCT is not therapy-related; the evolution of our case also makes it unlikely [21].

Although cytogenetic analysis of the original tumor was not available in this case to provide evidence that the MDS clone had evolved from the GCT clone, such evolution has been demonstrated in numerous previous cases [8, 17, 21, 24, 26, 31, 32] and seems indeed likely in this instance. On each occasion, cytogenetics revealed numerical and structural abnormalities which showed significant cell-to-cell variation. Our patient developed MDS 30 months after the initial GCT diagnosis. This time-course is somewhat longer than typical with a previous case series suggesting a median time from diagnosis of GCT to hematologic disorder of 5 months (range, 0–32 months) with approximately a third presenting simultaneously [21]. Following this, in a very short time-span, a MYC translocation was acquired, driving one leukemic sub-clone towards an aggressive Burkitt-like ALL phenotype. This clone proved responsive to ALL-directed chemotherapy and allogeneic HSCT. However, a third malignant clone with completely different lineage rapidly evolved into an erythroidblastic leukemia phenotype. Relapsed disease of a different histologic sub-type despite allogeneic-HSCT is consistent with a previous report of bone marrow transplantation performed in this setting [24]. The dismal prognosis in these rare cases warrants novel therapeutic approaches targeting the multiple clones. In this way Leonard et al. recently described a case of GCT with concomitant AML which achieved a partial sustained remission for 6 months with targeted therapy after in vitro assays demonstrated an NRAS mutation common to both the GCT and the concomitant erythroleukemia [26].

Conclusions

GCTs have shown the pluripotent capacity of transforming into malignancies of diverse origin; most commonly sarcoma. However mediastinal GCT can transform into unusual and diverse hematologic malignancies, likely from an initial “hematologic malignancy precursor” derived from the GCT [32]. Our case demonstrates the rapid sequential transformation into three distinct hematological malignancies: MDS, B-ALL with MYC rearrangement and pure erythroid leukemia despite aggressive treatment. As in previously reported cases, allogeneic-HSCT likely prolonged survival but was ultimately ineffective at preventing malignant transformation. Hematological diseases that arise from non seminomatous GCT show an aggressive and fatal course despite intensive treatment; novel therapeutic approaches targeting the pluripotent clone are needed to improve the outcome of these patients.

Abbreviations

ACE: Chemotherapy regimen for germ cell tumors, consisting of dactinomycin, etoposide and cyclophosphamide (see main text); ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; B-ALL: B-cell acute lymphoblastic leukemia; BM: Bone marrow; B-HEG: Beta-human chorionic gonadotrophin; FISH: Fluorescence in-situ hybridization; FLAG-IDA: Chemotherapy regimen for acute leukemias consisting of fludarabine, cytarabine, G-CSF and idarubicin (see main text); G-CSF: Granulocyte colony stimulating factor; GCT: Germ cell tumor; HSCT: Hematopoietic stem cell transplantation; i(12p): Isochromosome 12p; IV: Intra-venous; MDS: Myelodysplastic syndrome; MB: Bone marrow; B-HEG: Beta-human chorionic gonadotrophin; MRI: Magnetic resonance imaging; MUD: Matched unrelated donor; NSGCT: Non seminomatous germ cell tumor; POMB: Chemotherapy regimen for germ cell tumors, consisting of cisplatin, vincristine, methotrexate and bleomycin (see main text).

Acknowledgements

The authors would like to thank all members of the clinical team involved in the patient’s care, as well as the patient’s family.

Authors’ contributions

MSC was responsible for acquisition of the data and initial drafting of the manuscript, and was involved in the clinical care of the patient. EHMM was responsible for editing and updating the initial manuscript. PM was responsible for cytogenetic analysis of the patient’s bone marrow samples. EO was in charge of clinical management of the patient and interpretation of clinical data. All authors read and approved the final manuscript.

Funding

There are no funding grants supporting this publication.

Availability of data and materials

The key data supporting the conclusions of this article are included within the article. Further data including full cytogenetic reports are available on request.

Ethics approval and consent to participate

This was not a prospective study and therefore ethics approval/prospective consent for participation is not applicable.

Consent for publication

Written informed consent was obtained from the patient’s next of kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Cancer, Ageing & Somatic Mutation Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK. 2 Haematology Department, Hammersmith Hospital, Imperial NHS Trust, London, UK. 3 Centre for Haematology, Department of Immunology & Inflammation, Imperial College London, London, UK. 4 SIHMDS, Hammersmith Hospital, Imperial NHS Trust, London, UK.

Received: 18 June 2019   Accepted: 14 October 2020

Published online: 17 November 2020

References

1. McKenzie JK, Heerema-McKenney A, Rouse RV. Extragonadal germ cell tumors: a review with emphasis on pathologic features, clinical prognostic variables, and differential diagnostic considerations. Adv Anat Pathol. 2007;14(2):69–92.
2. Honecker F, Stoop H, Mayer F, Bokemeyer C, Castrillon DH, Lau YF, et al. Germ cell lineage differentiation in non-seminomatous germ cell tumours. J Pathol. 2006;208(3):395–400.
3. Bhardwaj A, Ro IV, Ayala AG. An overview of testicular germ cell tumors. Arch Pathol Lab Med. 2007;131(8):1267–80.
4. Chaganti RSK, Houldsworth J. Genetics and biology of adult human male germ cell tumors. Cancer Res. 2000;60:1475–82.
5. Donadio AC, Motzer RJ, Bajorin DF, Kantoff PW, Sheinfeld J, Houldsworth J, et al. Chemotherapy for teratoma with malignant transformation. J Clin Oncol. 2003;21(23):4265–91.
6. Chaganti RSK, Ladanyi M, Samaniego F, Offit K, Reuter VE, Jhanwar SC, et al. Leukemic differentiation of a mediastinal germ cell tumor. Genes Chromosome Cancer. 1989;1(1):83–7.
7. Ladanyi M, Samaniego F, Reuter VE, Motzer RJ, Jhanwar SC, Bosl GJ, et al. Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors. J Natl Cancer Inst. 1990;82(23):221–7.
8. Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, et al. Hematico- disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst. 2000;92(1):54–61.
9. Fielding A. A trial looking at treatment for adults with acute lymphoblastic leukaemia (UKALL14). Cancer Research UK trial number CRUK/09/006.
10. Porti G, Corona G, Vignozzi L, Krausz C, Maggi M. Klinefelter syndrome: a clinical and therapeutic update. Sex Dev. 2010;4(4):249–58.
11. Aguirre D, Nieto K, Lazos M, Peña YR, Palma I, Kofman-Alfaro S, et al. Extragonadal germ cell tumors are often associated with Klinefelter syndrome. Hum Pathol. 2006;37(4):477–80.
12. Lachman MF, Kim K, Koo BC. Mediastinal teratoma associated with Klinefelter’s syndrome. Br J Haematol. 1994;88(1):196–8.
13. Nichols CR, Roth BJ, Heerema N, Griep J, Tricot G. Hematologic neoplasia associated with primary mediastinal nonseminomatous germ cell tumors. J Clin Oncol. 1990;8(23):221–7.
14. Ganmore I, Smooha G, Izraeli S. Constitutional aneuploidy and cancer predisposition. Hum Mol Genet. 2009;18(R1):84–93.
15. Ökada Y, Nishikawa R, Matsutani M, Louis DN. Hypomethylated X chromosome gain and rare isochromosome 12p in diverse intracranial germ cell tumors. J Neurooncol Exp Neurol. 2002;61(6):313–8.
16. Motzer RJ, Amsterdarn A, Prieto V, Sheinfeld J, Murtu W, Mazumdar M, et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol. 1998;159(1):133–8.
17. Woodruff K, Wang N, May W, Adrone E, Denny C, Feig SA. The clonal nature of mediastinal germ cell tumors and acute myelogenous leukemia. A case report and review of the literature. Cancer Genet Cyto genet. 1995;79(1):25–31.
18. Bosl GJ, Ison DH, Rodriguez E, Motzer RJ, Reuter VE, Chaganti RSK. Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst. 1994;86(3):349–55.
19. Serrano M, Rodríguez García JL, Ferro T, Fraile G, Laraña JG. Mediastinal germ cell tumour and myelodysplastic syndrome. Postgrad Med J. 1991;67:313.
20. Vlasveld LT, Splinter TA, Hagemeijer A, Van Lom K, Lowenberg B. Acute myeloid leukaemia with +i(12p) shortly after treatment of mediastinal germ cell tumour. Br J Haematol. 1994;88(1):196–8.
21. Nichols CR, Roth BJ, Heerema N, Griepe J, Tricot G. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med. 1993;329(20):1425–9.
22. Keung YK, Liang R, Chiou EKW. Acute leukemia associated with mediastinal germ cell tumor: De novo versus therapy-related leukemia. West J Med. 1993;158(4):409–10.
23. Downie PA, Moldwin RL, Allen RJ, Smith SD, Vogelzang NJ, Le Beau MM, et al. Establishment of a leukemia cell line with i(12p) from a patient with a mediastinal germ cell tumor and acute lymphoblastic leukemia. Cancer Res. 1994;54(18):5099–5104.
24. Kassis Y, Penther D, Schneider R, Callat M-P, Bastard C, Vannier J. Malignant transformations in a patient with a mediastinal germ cell tumour: lack of efficacy of bone marrow transplantation after chemotherapy on tumour recurrence. BMJ Case Rep. 2012;2012;bcrcr0820114663.
25. Yu N, Kim HR, Cha YJ, Park EK, Kim JW. Development of acute megakaryoblastic leukemia with isochromosome (12p) after a primary mediastinal germ cell tumor in Korea. J Korean Med Sci. 2011;26(8):1099–102.
26. Leonard JT, Raiss PW, Dunlap J, Hayes-Lattin B, Tyner JW, Taer E. Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MK6 inhibitor as an active clinical agent. J Hematol Oncol. 2016;9(1):1–6.
27. Fang LH, Shih LS, Lee PI, Chen WT, Chen RL. Mediastinal germ cell tumor-associated histiocytic proliferations treated with thalidomide plus chemotherapy followed by alemtuzumab-containing reduced intensity allogeneic peripheral blood stem cell transplantation: a case report. Medicine. 2016;95(2):1–5.
28. Park JH, Choi HW, Seo BY, Kang MG, Kim SH, Baek HJ, et al. Immature teratoma and subsequent acute promyelocytic leukemia in a pediatric patient with XYY syndrome. Ann Lab Med. 2015;35(5):544–7.
29. Maese L, Li KD, Xu X, Affy Z, Paxton CN, Putnam A. Acute leukemia and concurrent mediastinal germ cell tumor: case report and literature review. Fetal Pediatr Pathol. 2017;36(2):168–76.
30. Maddox NA, Rabatic BM, Zaenger D, Marascio JA, Marchan EM, Dasher BG, et al. Mediastinal germ cell tumors and development of secondary leukemia and solid tumors. J Clin Oncol. 2016;34(15_suppl):e16043.
31. Hirai Y, Yoshimasu T, Oura S, Okamura Y. Mediastinal germ cell tumor associated with acute myeloid leukemia and growing teratoma syndrome: Interact Cardiovasc Thorac Surg. 2011;12(1):96–7.
32. Taylor J, Donoghue M, Rampal RK, Tamaí R, Tallman MS, Feldman DR, et al. Hematologic malignancies arising in patients with germ cell tumors: secondary somatic differentiation of hematopoietic malignancies from germ cell precursors. Blood. 2018;132(1):87LP – 87.